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Introduction: The incidence and progression of many autoimmune diseases are sex-biased, which might be explained
by the immunomodulating properties of endocrine hormones. Treatment with estradiol potently inhibits experimental
autoimmune arthritis. Interleukin-17-producing T helper cells (Th17) are key players in several autoimmune diseases,
particularly in rheumatoid arthritis. The aim of this study was to investigate the effects of estrogen on Th17 cells in
experimental arthritis.
Methods: Ovariectomized DBA/1 mice treated with 17β-estradiol (E2) or placebo were subjected to collagen-induced
arthritis (CIA), and arthritis development was assessed. Th17 cells in joints and lymph nodes were studied by flow
cytometry. Lymph node Th17 cells were also examined in ovariectomized estrogen receptor α–knockout mice (ERα−/−)
and wild-type littermates, treated with E2 or placebo and subjected to antigen-induced arthritis.
Results: E2-treated mice with established CIA showed reduced severity of arthritis and fewer Th17 cells in joints
compared with controls. Interestingly, E2-treated mice displayed increased Th17 cells in lymph nodes during the early
phase of the disease, dependent on ERα. E2 increased the expression of C-C chemokine receptor 6 (CCR6) on lymph
node Th17 cells as well as the expression of the corresponding C-C chemokine ligand 20 (CCL20) within lymph nodes.
Conclusions: This is the first study in which the effects of E2 on Th17 cells have been characterized in experimental
autoimmune arthritis. We report that E2 treatment results in an increase of Th17 cells in lymph nodes during the early
phase of arthritis development, but leads to a decrease of Th17 in joints during established arthritis. Our data suggest
that this may be caused by interference with the CCR6-CCL20 pathway, which is important for Th17 cell migration. This
study contributes to the understanding of the role of estrogen in the development of autoimmune arthritis and opens
up new fields for research concerning the sex bias in autoimmune disease.Introduction
Sex influences susceptibility to autoimmune diseases such
as rheumatoid arthritis (RA), for which the female-to-
male ratio is 3:1. The peak incidence of RA in women co-
incides with the time of menopause, when estrogen levels
rapidly drop, connecting sex hormones to disease etiology
[1]. In contrast, men have rather continuous levels of es-
trogen throughout their adult lives, and estrogen levels are
lower in postmenopausal women than in men of corre-
sponding age [2]. During pregnancy, when sex hormone
levels rise, up to 75% of RA patients experience relief of* Correspondence: annica.andersson@rheuma.gu.se
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unless otherwise stated.disease symptoms [3]. In a well-established experimental
model of RA, collagen-induced arthritis (CIA), it has re-
peatedly been shown that estrogen ameliorates disease de-
velopment [4,5]. Regarding human RA, some studies
indicate that hormone replacement therapy including es-
tradiol might be beneficial; however, the results of studies
in this field are inconsistent. In one long-term study, re-
searchers reported improved disease activity scores and in-
creased bone mineral density after hormone replacement
therapy [6]. Secondary osteoporosis is common in RA pa-
tients; about 50% of postmenopausal women with RA
have a diagnosis of osteoporosis [7]. In contrast to RA, es-
trogen aggravates systemic lupus erythematosus [8]. In-
deed, estrogen is a potent immunomodulatory agent and
can exert stimulatory as well as regulatory effects on the
immune system, such as enhancing B cell antibodytral. This is an Open Access article distributed under the terms of the Creative
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ing T cell-dependent inflammation [9-12].
The cytokine interleukin (IL)-17A (referred to as IL-17)
is produced mainly by T helper 17 cells (Th17) and consti-
tutes the driving force in several autoimmune diseases. In
RA, Th17 cell frequency and level of synovial fluid IL-17
strongly correlate with disease activity [13]. Phase II clin-
ical trials on RA patients receiving anti-IL-17A treatment
resulted in significantly decreased disease activity scores
[14,15]. IL-17 augments joint inflammation by stimulating
synovial fibroblasts to produce CXCL8 (IL-8), thereby
attracting neutrophils to the joints [16,17]. Moreover, IL-
17 plays a role in inflammation-induced bone loss by
stimulating osteoclastogenesis [18]. Migration of Th17
cells to the site of inflammation is mainly orchestrated by
the interaction of C-C chemokine ligand 20 (CCL20) with
C-C chemokine receptor 6 (CCR6) that is expressed on
the Th17 cell [19].
Effects of estrogen on Th17 cells have mostly been
studied in the context of experimental multiple
sclerosis—experimental autoimmune encephalomyelitis
(EAE)—another Th17-driven disease where estrogen is
protective. Estrogen decreases production of IL-17 in EAE
and inhibits Th17 differentiation and disease progression,
dependent on estrogen receptor α (ERα) in T cells [20,21].
However, effects of estrogen on the Th17 cell population
in arthritis have been scarcely studied, and are limited to
studies on IL-17 production. We have recently shown
that estrogen decreases splenic IL-17 production in vitro
in antigen-induced arthritis (AIA) in an ERα-dependent
manner [22]. Furthermore, the estrogen metabolite 2-
methoxyestradiol decreased IL-17 mRNA in arthritic
joints in collagen-antibody induced arthritis [23].
In this study, we thoroughly characterized estrogenic
effects on Th17 cell phenotype and localization in ex-
perimental arthritis. We demonstrate that estrogen reg-
ulates localization of Th17 cells during development of
CIA, resulting in increased Th17 in lymph nodes (LNs)
but decreased Th17 in joints. In addition, the E2-
mediated increase in Th17 cells in LNs is dependent on
ERα. Moreover, estrogen increases CCR6 expression on
LN Th17 cells and enhances production of CCL20
within LNs, possibly resulting in Th17 cell accumula-
tion in the LNs and reduced migration of Th17 cells to
joints. Subsequently, IL-17-mediated destruction of
joints is inhibited. Our study increases the understand-




The study was approved by the regional ethical review
board in Gothenburg, Sweden. Female DBA/1 mice
(Taconic Europe A/S, Ry, Denmark), total ERα-inactivatedmice (ERα−/−) and wild-type (WT) littermates were elec-
tronically tagged and kept in groups of five to ten animals
in each cage under standard environmental conditions.
The mice were fed standard laboratory chow and tap
water ad libitum. ERα−/− mice have a deletion in exon 3 of
the ERα gene and do not express any of the isoforms of
the ERα protein. ERα−/− mice and WT (ERα+/+) litter-
mates were inbred C57BL/6 mice. They were generated
by breeding male ERα+/− with female ERα+/− mice, as
previously described [24].
Ovariectomy
All mice were ovariectomized (OVX) initially. At 8 to
10 weeks of age, ovaries were removed through a mid-
line incision of the skin followed by flank incisions of
the peritoneum, and the skin was closed with metallic
clips. Surgery was performed with the mice under
isoflurane-induced anesthesia (Baxter Healthcare, Chicago,
IL, USA), and carprofen (Rimadyl; Orion Pharma Animal




The CIA experimental protocol is depicted in Figure 1.
12 days after ovariectomy, DBA/1 mice were im-
munized with chicken collagen type II (100 μg/mouse;
Sigma-Aldrich, St Louis, MO, USA) in Freund’s in-
complete adjuvant (Sigma-Aldrich) supplemented with
Mycobacterium tuberculosis H37 RA (50 μg/mouse;
BD, Franklin Lakes, NJ, USA) (day 0), as described else-
where [25]. Immunization was repeated after 21 or
28 days, without mycobacteria. Arthritis development
was monitored and scored by examination of mice
every second or third day in a blinded manner with re-
spect to treatment groups. Arthritis severity was
assessed by using scores (0 to 3) for each paw, giving a
maximum of 12 points for each mouse, determined as
follows: 1 = swelling or erythema in one joint, 2 = swell-
ing or erythema in two joints, 3 = severe swelling or
erythema of more than two joints, or ankylosis of the
entire paw. Experiments were terminated at several
time points after the first immunization (Figure 1).
Antigen-induced arthritis
Two weeks after ovariectomy, ERα−/− mice and WT
littermates were subjected to AIA by immunization at
day 0 with methylated bovine serum albumin (mBSA; in
phosphate-buffered saline (PBS), 0.2 mg/mouse; Sigma-
Aldrich) emulsified in Freund’s complete adjuvant
(Sigma-Aldrich) injected at the base of the tail, followed
by intraarticular injection of mBSA (0.3 mg/mouse) into
one knee at day 7. The AIA experiment was terminated
day 14. AIA is described in detail elsewhere [22].
COLLAGEN-INDUCED ARTHRITIS (CIA)
Day -12 21 
or 28
0 14 23 35 49





Figure 1 Experimental setup for collagen-induced arthritis. Female DBA/1 mice were ovariectomized (OVX) at 8 to 10 weeks of age and
simultaneously received an implanted slow-release pellet containing 17β-estradiol (E2; 0.83 μg/day) or corresponding placebo. After 12 days of
rest, they were immunized subcutaneously at the base of the tail with collagen type II and Freund’s adjuvant (day 0), which was repeated at day
21 or 28. Experiments were terminated at days 14, 23, 35 and 49 after the first immunization. Days 14 and 23 were considered as time points in
the (asymptomatic) induction phase of collagen-induced arthritis (CIA), whereas days 35 and 49 were defined as established (symptomatic) CIA.
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Mice were administered subcutaneous slow-release im-
plants with 17β-estradiol (E2; Innovative Research of
America, Sarasota, FL, USA) or placebo at the time
point of OVX, resulting in daily doses of 0.83 μg of E2
per mouse. In one CIA experiment, mice received only
3 days of E2 treatment, administered by subcutaneous
injections during days 20 to 22, using 17β-estradiol-3-
benzoate (1 μg/mouse/day: Sigma-Aldrich) in inert oil
(Miglyol 812; Recip, Årsta, Sweden), and control mice
received oil only. As described earlier, mice treated with
estradiol in doses similar to those used herein obtain
serum estradiol of 10 to 25 pg/ml, which in healthy mice
corresponds to low diestrus levels [26]. Successful OVX
and estrogen treatment was confirmed by weighing uteri
at termination (data not shown).
Tissue collection and histological examination
At termination, mice were anesthetized with ketamine
(Ketalar; Pfizer AB, Täby, Sweden) and medetomidine
(Domitor; Orion Pharma Animal Health), bled, and killed
by cervical dislocation. Sera were stored at −20°C until
use. Paws from CIA mice were either placed in RPMI
1640 for isolation of joint cells or placed in 4% formalde-
hyde, decalcified, embedded in paraffin, sectioned and
stained with hematoxylin and eosin. Synovitis and erosions
were separately scored from 0 to 3: 0 = normal ap-
pearance, 1 = mild, 2 = moderate or 3 = severe synovitis/
erosion of cartilage and bone. A histopathological index
was constructed by adding the scores from the evalu-
ated joints in each animal. LNs draining the joints in
CIA (subiliac, popliteal, sciatic, proper and accessory
axillary) and in AIA (subiliac, popliteal) [27] were pooled
and stored in PBS until cell preparation, or snap-frozen, or
kept in RNAlater (Qiagen, Hilden, Germany), then stored
in −70°C for mRNA analysis.Preparation of cells and flow cytometric analysis
To isolate cells from the joints of arthritic mice, paws were
stripped from skin and digested with collagenase IV
(Sigma-Aldrich) and subsequently passed through a 70-
μm cell strainer. LNs were mashed through a 70-μm cell
strainer and washed in PBS. Cells were counted in an au-
tomated counter (Sysmex, Noderstedt, Germany). For
analysis of intracellular cytokines, cells were suspended in
complete medium (phenol red-free RPMI 1640 (PAA
Laboratories, Pasching, Austria) supplemented with 10%
dextran-coated charcoal hormone-stripped fetal calf
serum (Sigma-Aldrich), 1% 2-mercaptoethanol (Sigma-
Aldrich) and 1% penicillin-streptomycin-L-glutamine so-
lution (Sigma-Aldrich)), and then stimulated with phorbol
12-myristate 13-acetate (PMA) (50 ng/ml; Sigma-Aldrich),
ionomycin (1 μg/ml: Sigma-Aldrich) and GolgiPlug (BD)
for 4 hours at 37°C and 5% CO2. Fluorochrome-
conjugated anti-mouse antibodies were used for intracel-
lular staining of IL-17A (eBioscience, Vienna, Austria),
interferon γ (IFNγ) (BD) and Foxp3 (eBioscience) in
permeabilization buffer (eBioscience) and for extracellular
staining of CD4, CD11b and CD25 (BD); CCR2 and
S1PR1/EDG-1 (R&D Systems, Minneapolis, MN, USA);
and CCR6, CCR7, F4/80 and Gr-1 (BioLegend, San Diego,
CA, USA). All analyses started with gates on singlet cells;
thereafter, Th17 (CD4+IL-17+), Th1 (CD4+IFNγ+), and
regulatory T cells (Treg; CD4+Foxp3+CD25+) were gated
on lymphocytes, and neutrophils (CD11b+F4/80−Gr-1hi)
were gated on live cells. For each individual, absolute
numbers of cell populations were obtained by multiply-
ing the frequency of the cell population obtained by
flow cytometry by the total cellularity of either one
subiliac LN or the four paws. Samples were run on a
BD FACSCanto II flow cytometer, and data were proc-
essed using FlowJo 8.8.6 software (Tree Star, Ashland,
OR, USA).
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The ELISPOT assay was performed according to manu-
facturer’s instructions (eBioscience). Added to each well
were 0.5 to 1 × 105 joint cells, or all migrated LN cells
from the chemotaxis assay, followed by stimulation with
PMA and ionomycin. After incubation at 37°C and 5%
CO2 for 40 to 42 hours, spots were developed and
counted.
Chemotaxis assay
LN cells (from CIA mice treated with E2 or placebo, day
35) were cultured in a 24-well, 5-μm pore size Transwell
system (Corning Costar, Corning, NY, USA). A total of
2 × 106 cells were placed on top of the transwell, and
CCL20 (50 ng/ml; R&D Systems), or complete medium
only, was added to the lower chamber. After 4 hours of in-
cubation (37°C and 5% CO2), migrated cells were put on
an IL-17 ELISPOT assay, performed as described above.
The percentage CCL20-induced migration of IL-17-
producing cells in each treatment group was calculated as
follows: number of IL-17 spot-forming cells (SFCs) after
migration toward CCL20 minus number of IL-17 SFCs
after migration toward medium only (background), di-
vided by number of IL-17 SFCs before chemotaxis assay.
ELISA
Serum CCL20 quantification was performed using a
mouse CCL20/macrophage inflammatory protein 3α
DuoSet enzyme-linked immunosorbent assay (ELISA) kit
(R&D Systems). Plates (Corning Costar) were coated with
anti-CCL20 monoclonal antibody and blocked (1% BSA).
After adding samples, detection antibody and streptavidin-
horseradish peroxidase, plates were developed with
3,3′,5,5′-tetramethylbenzidine (Sigma-Aldrich), stopped
with 1 M H2SO4 and read at an absorbance of 450 nm,
with wavelength correction at 540 nm, on a SpectraMax
Plus (Molecular Devices, Sunnyvale, CA, USA). Serum
sphingosine-1-phosphate (S1P) levels were determined by
using a competitive S1P ELISA kit (Echelon Biosciences,
Salt Lake City, UT, USA), according to the manufacturer’s
instructions.
Real-time quantitative PCR
Subiliac LNs were homogenized in TissueLyser II (Qiagen),
and total RNA was extracted using the RNeasy Mini kit in
QIAcube (Qiagen). RNA content, purity and integrity were
determined with NanoDrop ND-1000 (NanoDrop Tech-
nologies, Wilmington, DE, USA) and Experion (Bio-Rad
Laboratories, Hercules, CA, USA). A high-capacity cDNA
reverse transcription kit (Applied Biosystems, Foster City,
CA, USA) was used to perform cDNA synthesis. Real-time
quantitative PCR was performed at the Genomics Core
Facility, University of Gothenburg, using a Biomek FX pip-
etting robot (Beckman Coulter, Fullerton, CA, USA) andan ABI PRISM 7900 HT instrument (Applied Biosystems).
The genes of interest and endogenous controls were in-
vestigated with inventoried TaqMan Gene Expression
assays (Ccl20: Mm01268754_m1, Ccl2: Mm00441242_
m1, Ccl12: Mm01617100_m1, Ccl19: Mm00839967_
g1, Ccl21: Mm03646971_gH, 18 s: Mm03928990_g1,
B2m: Mm00437762_m1, Eef2: Mm01171435_gH, Hprt1:
Mm01545399_m1, Rpl13a: Mm01612986_gH) and Taq-
Man Gene Expression Master Mix (Applied Biosystems).
mRNA expression analysis was performed with RQ
Manager software version 1.2.1 (Applied Biosystems). The
Eef2 and Hprt1 combination was identified as the opti-
mal normalization gene pair using NormFinder software
(Molecular Diagnostic Laboratory, Aarhus University
Hospital, Aarhus, Denmark). Gene expression values
were calculated using the 2−ΔΔCT relative quantification
method, wherein the placebo group was designated the
calibrator [28].
Statistical analysis
Statistical evaluations were performed using IBM SPSS
software 20.0.0 (IBM, Armonk, NY, USA) and GraphPad
Prism version 6.0b software (GraphPad Software, La
Jolla, CA, USA). Student’s t-test was used for compari-
son of two independent groups. Whenever Levene’s test
revealed unequal variances between the groups, Welch’s
t-test was used instead. Logarithmic transformations
were used when appropriate to ensure normal distribu-
tion of data. Analysis of covariance was used when ad-
justments for covariates were needed (that is, when two
experiments were pooled). The area under the curve for
severity of arthritis was calculated by the trapezoidal
method. Scoring of severity of arthritis and histopatho-
logical index were performed using an ordinal scale requir-
ing non-parametric statistical evaluation, and therefore the
Mann–Whitney test was used. A log-rank test was per-
formed to compare the incidence of arthritis between
treatment groups. P-values <0.05 were considered statisti-
cally significant.
Results
E2-treated mice have fewer Th17 cells in joints and less
severe arthritis than placebo controls
Female DBA/1 mice underwent OVX to reduce en-
dogenous hormone production. Mice were randomly
assigned to treatment with E2 or placebo and subjected
to CIA, and the development of arthritis was assessed.
E2 dramatically decreased the severity and incidence of
arthritis and delayed the onset of disease (Figure 2A,B).
Histological examination of paws confirmed the E2-
mediated amelioration of arthritis, regarding the pres-
ence of both synovitis and erosions on cartilage and
bone (Figure 2C,D). We investigated the effect of E2


















































































Figure 2 Effects of estrogen on arthritis development in the collagen-induced arthritis model. DBA/1 mice were ovariectomized, subjected to
collagen-induced arthritis (CIA) and treated with 17β-estradiol (E2; 0.83 μg/day) or placebo. Arthritis development was macroscopically assessed every
second or third day by a blinded examiner, yielding a maximum of 12 points per mouse (single experiment with n = 14 mice/group). (A) Severity of
arthritis is expressed as median and interquartile range. The area under the curve was calculated for each treatment group and differences between
groups were analyzed by Mann–Whitney test. CII, Collagen type II. (B) Incidence of arthritis is presented as Kaplan-Meier curves and analyzed by
log-rank test. (C) Microscopic synovitis and erosions on bone and cartilage were assessed in paw sections stained with hematoxylin and eosin, from
placebo- or E2-treated mice with CIA, terminated on day 49. Data are median with interquartile range, Mann–Whitney test, n = 5 or 6 mice/group in
a single experiment. Representative sections from each treatment group are shown in (D). Original magnification, ×20. *P <0.05, ***P <0.001.
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mice had fewer IL-17-producing cells in their joints
compared with mice administered placebo treatment
(Figure 3A). In order to characterize the IL-17-producing
cells in the joints, flow cytometry was used. An experi-
ment terminated in the arthritis phase (day 35) showed
that Th17 cell numbers were lower in joints of E2-treated
mice (Figure 3B). Reduction in IL-17-producing cells was
accompanied by decreased numbers of neutrophils in the
joints of E2-treated mice (Figure 3C). Treatment with E2
inhibited arthritis development and was associated with
decreased numbers of Th17 cells and neutrophils in joints.
E2 increases the frequency of lymph node Th17 cells in
early CIA
In order to characterize the effects of E2 on Th17 cell de-
velopment in arthritis, experiments were terminated at
different time points during the induction phase of CIA(Figure 1), and Th17 cells in LNs were studied. Surpris-
ingly, E2 increased the proportion of Th17 cells in LNs
during the induction phase of CIA (days 14 and 23),
whereas this effect disappeared in the arthritis phase (day
35) (Figure 4A,B). In order to investigate if E2 caused in-
creased differentiation of Th17 cells in the LNs during the
induction of CIA, or if the effect of E2 was more rapid, we
performed an experiment with short-term E2 treatment.
OVX mice were subjected to CIA as in the previous ex-
periments, but they were treated with E2 for only 3 days
(days 20 to 22), and the experiment was terminated on
day 23. Interestingly, short-term E2 treatment also re-
sulted in an increase of Th17 cells in the LNs, compared
with controls (Figure 4C), clearly demonstrating that the
effect of E2 on Th17 cells is rapid. Other populations of
CD4+ T cells involved in development or regulation of
arthritis, such as Th1 cells (Figure 4D) and Treg cells











































































Figure 3 Effects of estrogen on Th17 cells in joints of mice with established collagen-induced arthritis. DBA/1 mice were ovariectomized,
subjected to collagen-induced arthritis (CIA) and treated with 17β-estradiol (E2; 0.83 μg/day) or placebo. (A) Joint cells from mice with CIA terminated
day 49 were stimulated in triplicates with phorbol 12-myristate 13-acetate and ionomycin for 40 to 42 hours in interleukin (IL)-17 ELISPOT assay. The
number of spot-forming cells (SFCs) was counted in a blinded manner these are shown as SFCs per total number of cells in wells. Total numbers of
(B) T helper 17 cells (Th17; IL-17+CD4+) and (C) neutrophils (CD11b+F4/80−Gr-1hi) in joints from mice with CIA terminated day 35 were determined by
flow cytometry. The absolute number of cells was derived by multiplying the frequency of Th17 cells or neutrophils by the total number of cells
acquired from an automated cell counter in a corresponding sample. All data shown are arithmetic mean ± SEM derived from single experiments with
n = 8 or 9 mice/group. *P <0.05 (Student’s t-test).
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present in antigen-induced arthritis and is dependent on ERα
To verify that the effect of E2 on Th17 cells in arthritis
was not specific for the CIA model, AIA was performed
in placebo- or E2-treated OVX mice. We have recently
shown that E2 inhibits AIA in an ERα-dependent man-
ner [22]. In line with data on Th17 in the CIA model, E2
increased the frequency of Th17 cells in LNs of mice
with AIA (Figure 4F, left). However, E2 did not change
the frequency of LN Th17 cells in mice lacking ERα
(Figure 4F, right).
Absolute numbers of lymph node Th17 cells are
increased by E2 in early CIA
To further establish the E2-mediated increase in LN
Th17 cells, absolute numbers of LN Th17 cells were an-
alyzed. One subiliac LN was dissected from each mouse
(CIA, day 14), and total numbers of lymphocytes were
counted and related to frequency of Th17 cells (obtained
by flow cytometry) to obtain absolute numbers of CD4+
cells and Th17 cells. In line with previous data on Th17
cell frequency in LNs (Figure 4B), the absolute numbers
of LN Th17 cells were higher in mice treated with E2
compared with placebo (Figure 5A), whereas the total
numbers of CD4+ cells were unaffected (Figure 5B).
E2 influences lymph node chemokine production and
chemokine receptor expression on Th17 cells
One explanatory mechanism for the increase of Th17
cells in the LNs during the induction phase of CIA could
be that E2 interferes with the ability of Th17 cells to
egress from LNs and migrate to joints. Therefore, wefurther characterized the effect of E2 on Th17 cell
migration-associated pathways during the induction
phase of CIA.
A fraction of both human and murine Th17 cells ex-
press the chemokine receptor CCR2 that mediates mi-
gration toward CCL2 and CCL12 [29-31]. We confirmed
expression of CCR2 on LN Th17 cells from mice with
CIA terminated day 14; however, irrespective of treat-
ment group, only a minor proportion (approximately
4.5%) of Th17 cells expressed CCR2 (Figure 6A). More-
over, the intensity of CCR2 expression on Th17 cells did
not differ between the treatment groups (Figure 6B,C).
We also analyzed mRNA levels of Ccl2 and Ccl12 in
whole LNs and found that E2 increased Ccl2 and Ccl12
compared with placebo-treated controls (Figure 6D,E).
The interaction between CCR6 and CCL20 plays an
important role in the migration of pathogenic Th17 cells
in arthritis, and a majority of Th17 cells express CCR6
(Figure 6F) [19]. We analyzed CCR6 expression on LN
Th17 cells from E2- and placebo-treated mice with early
CIA (day 14). Interestingly, we found that E2 increased
the proportion of CCR6+ cells in the Th17 population
(Figure 6F), as well as enhanced the expression of CCR6
on Th17 cells, in comparison to the placebo group
(Figure 6G,H). We considered the possibility that the
egress of CCR6+ Th17 cells from the LNs could be ham-
pered in E2-treated mice due to decreased production of
CCL20 in joints and reduced serum levels of CCL20.
However, serum CCL20 in mice with CIA terminated at
day 14 did not differ between the treatment groups
(mean ± SEM: placebo = 224.7 ± 16.13 vs. E2 = 212.4 ±
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Figure 4 Estrogenic effects on lymph node Th17 cells in collagen-induced arthritis and in antigen-induced arthritis. DBA/1 mice were
ovariectomized, subjected to collagen-induced arthritis (CIA) (A–E), or ovariectomized estrogen receptor α–knockout mice (ERα−/−) mice and
wild-type (WT) littermates were subjected to antigen-induced arthritis (AIA) (F) and treated with 17β-estradiol (E2; 0.83 μg/day) or placebo (A, B).
The frequency of T helper 17 (Th17) cells in lymph nodes (LNs) of CIA mice (terminated at day 14, n = 10 mice/group; at day 23, n = 8 to 10 mice/
group; at day 35, n = 7 to 9 mice/group). Data from day 14 is from one representative experiment out of three independent experiments in total;
otherwise, single experiments were performed. Representative flow cytometry plots are shown in (A). (C) Frequency of Th17 cells in LNs of CIA
mice (day 23, single experiment, n= 9 mice/group), with only 3 days of E2 treatment (days 20 to 22). (D,E) Frequencies of Th1 (D) and regulatory T cells
(Treg) (E) in LNs of CIA mice (day 14, n = 10 mice/group; day 23, n = 8 to 10 mice/group; single experiments). (F) In AIA, frequency of Th17 cells in LNs
(draining knee joints) was determined at day 14 (two independent experiments, in total n = 14 to 19 mice/group). To improve normal
distribution of data, some data were log-transformed prior to statistical analysis (B, D and E). Arithmetic mean ± SEM is shown in all graphs. Student’s
t-test was used (*P <0.05, **P <0.01).
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(CIA day 49). We then speculated that CCR6+ Th17 cells
might be retained in the LNs because of increased levels
of CCL20 within the LN tissue. Interestingly, we found in-
creased Ccl20 mRNA in LNs from E2-treated mice
(Figure 6I) with CIA day 14, revealing one possible mech-
anism for E2-induced retention of Th17 cells during arth-
ritis development.
In order to investigate if E2 could influence the function
of IL-17-producing cells, LN cells from CIA mice (day 35)
were used in an in vitro CCL20-induced chemotaxis assay.
The results showed that IL-17-producing cells from E2-
treated mice migrated better toward CCL20 than did cellsfrom placebo-treated mice (Figure 6J), which implicates a
functional relevance of the increased CCR6 expression on
Th17 cells after E2 treatment, as shown in Figure 6H.
Naïve T cells generally downregulate the expression of
CCR7 after activation to enable LN egress. We specu-
lated that E2 might sustain the expression of CCR7 on
Th17 cells and thereby hamper their egress from LNs.
However, regardless of treatment, LN Th17 cells (CIA,
day 14) did not express CCR7 at all (see Additional file
1: Figure S1A). As a positive control, CCR7 expression
was confirmed on CD4+ cells, but was not altered by E2
treatment (see Additional file 1: Figure S1B–D). mRNA













































Figure 5 Absolute numbers of lymph node CD4+ cells and
Th17 cells after estrogen treatment in early collagen-induced
arthritis. DBA/1 mice were ovariectomized, subjected to collagen-
induced arthritis (CIA) and treated with 17β-estradiol (E2; 0.83 μg/day)
or placebo. (A,B) Absolute number of T helper 17 (Th17) cells (A) and
CD4+ cells (B) in one subiliac lymph node (LN) of CIA mice (day 14,
n = 10 or 11 mice/group), obtained by multiplying cell population
frequencies obtained by fluorescence-activated cell sorting by total LN
cellularity. To improve normal distribution of data, some data were
log-transformed prior to statistical analysis (A). Arithmetic mean ± SEM
is shown in all graphs. Student’s t-test (B) or Welch’s t-test (A) was used
(*P <0.05).
Andersson et al. Arthritis Research & Therapy  (2015) 17:32 Page 8 of 12and Ccl21 was detected in whole LNs (CIA, day 14), and
the results show that Ccl19, but not Ccl21, was reduced
by E2 (see Additional file 1: Figure S1E,F).
E2 modulates S1PR1 expression on Th17 cells in CIA
S1P and its receptor S1PR1 are important in mediating
T cell egress from LNs [32]. The S1P gradient—with the
lowest levels in the LN and the highest in lymph and
blood—drives cell egress [33]. We hypothesized that the
E2-induced retention of Th17 cells in the LNs could be
caused by decreased expression of S1PR1 on Th17 cells
or modulation of serum S1P levels. Unexpectedly, E2 in-
creased the frequency of S1PR1+ Th17 cells, as well as
the median fluorescence intensity of S1PR1 on Th17
cells (Figure 7A to C), in LNs of mice with CIA at day
14. Moreover, the levels of serum S1P at this time point
did not differ between treatment groups (Figure 7D).
Discussion
Our study shows that beneficial treatment with E2 in ex-
perimental arthritis is connected to a modulated distri-
bution of Th17 cells whereby E2 increases Th17 cells in
LNs and decreases Th17 in joints. In addition, we show
that E2 alters the Th17 phenotype with regard to migra-
tory function, as E2 increases CCR6 and S1PR1 on Th17
cells and also influences LN chemokine expression. We
suggest that increased CCR6 on Th17 cells, as well asincreased corresponding ligand (CCL20) within LNs, re-
sults in retention of Th17 cells in LNs during the induc-
tion phase of CIA. Probably, Th17 cell migration to
joints is abrogated, which subsequently leads to de-
creased recruitment of neutrophils to the joints, reduced
inflammation and alleviation of joint erosions.
The interaction between chemokines and chemokine
receptors directs systemic T cell trafficking as well as
localization of T cells within tissue microenvironments
[34]. Migration of Th17 cells to the joints in arthritis is
orchestrated mainly by CCL20 and corresponding recep-
tor CCR6 expressed on Th17 cells [19]. E2 induces the
expression of CCR1–CCR5 in murine splenic CD4+ T
cells [35] and dose-dependently increases CCR6 in hu-
man lymphoblastoid cells [36]. In this study, we demon-
strate that E2 upregulates the expression of CCR6 on
Th17 cells (Figure 6G and H). Moreover, the E2-induced
expression of CCR6 on Th17 cells is indeed functional,
as cells from E2-treated CIA mice migrated better to-
ward CCL20 in vitro compared with placebo-treated
mice (Figure 6J). Probably, E2 directly affects transcrip-
tion of CCR6 because the presence of two ER elements
in the human Ccr6 gene has been predicted by database
studies [36], although this has not been studied in mice.
Despite increased expression of CCR6 on LN Th17 cells,
we found fewer Th17 cells in joints of E2-treated mice
compared with placebo (Figure 3B). We report that E2
increases Ccl20 mRNA in LNs (Figure 6I). CCL20 is
produced predominantly in response to inflammation,
by, for example, macrophages, dendritic cells and syn-
ovial fibroblasts [37]. We speculate that the increased
Ccl20 mRNA levels in LNs that we report could be ex-
plained by E2-mediated stimulation of CCL20 produc-
tion from LN resident dendritic cells, macrophages or
lymphoid stromal cells. Indeed, dendritic cells express
ER, and estrogen has vast effects on these cells (reviewed
in [38]). However, Th17 cells generated in vitro can also
produce CCL20 [19]. To exclude the possibility that
estrogen-mediated increase of Ccl20 mRNA is solely an
effect of increased Th17 cells, LN cells from mice (CIA
day 14) treated with E2 or placebo were stimulated
in vitro with plate-bound anti-CD3. Supernatants were
collected after 2 days and assessed in CCL20 ELISA, but
CCL20 was undetectable in all samples. Hence, we con-
clude that CCL20 in LNs is most likely produced by
other cells than T cells.
We demonstrate that E2 increases the expression of
mRNA encoding Ccl2 and Ccl12, in addition to Ccl20,
in the LNs (Figure 6D,E). These data are supported by a
study showing that estrogen is a potent inducer of CCL2
and CCL12 secretion from mouse splenocytes [39]. We
confirmed expression of CCR2 on Th17 cells; however,
in accordance with a previous study [29], we could find
expression of CCR2 only on a very small fraction of
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Figure 6 Th17 chemokine receptor expression and corresponding lymph node chemokine expression after estrogen treatment in collagen-
induced arthritis. DBA/1 mice were ovariectomized, subjected to collagen-induced arthritis (CIA) and treated with 17β-estradiol (E2; 0.83 μg/day)
or placebo. (A–C) Frequency of C-C chemokine receptor 2-positive (CCR2+) cells of T helper 17 (Th17) cells (A) and median fluorescence intensity
(MFI) of CCR2 on Th17 cells (B,C) in lymph nodes (LNs) from CIA mice (day 14, single experiment with n = 10 or 11 mice/group). (B) Representative
fluorescence-activated cell sorting (FACS) analysis plot where fluorescence minus one (FMO) is control. (D,E) mRNA expression of Ccl2 (D) and Ccl12
(E) in LNs of CIA mice (day 14, single experiment, n = 9 or 10 mice/group), determined by real-time quantitative PCR. (F–H) Frequency of CCR6+ cells
of Th17 (F) and MFI of CCR6 on Th17 cells (G,H) in LNs of CIA mice (day 14, single experiments, n = 9 or 10 mice/group). (G) Representative FACS plot
where FMO is control. (I) mRNA expression of Ccl20 in LNs of CIA mice (day 14, data pooled from two experiments, n= 20 mice/group). (J) CCL20-
specific migration of interleukin (IL)-17+ cells. LN cells from mice with CIA (day 35) were put on a transwell assay, with CCL20 in the lower chamber,
and the frequency of migrated cells was evaluated with an IL-17 ELISPOT assay. Data are representative of two independent experiments (n= 3 mice/group).
To improve normal distribution of data, some data were log-transformed prior to statistical analysis (A, C, F and H). Bars or lines show arithmetic
mean ± SEM (A, C, F, H and J) or geometric mean (D, E and I). Student’s t-test (A, C–F, H and J) or analysis of covariance with experiment as covariate
(I) was used (*P <0.05, **P <0.01).
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ment groups (Figure 6A to C). Therefore, we conclude
that the CCR2-CCL2/CCL12 pathway is not likely the
major pathway responsible for E2-mediated retention of
Th17 cells in LNs.
Another important pathway in T cell LN egress is S1P
and its receptors (for example, S1PR1) [32]. Pharmaco-
logic disruption of the S1P–S1PR1 interaction ameliorates
CIA as a consequence of blocked lymphocyte egress from
LNs [40]. Contradictorily, we report that E2—despite
ameliorating CIA—increases S1PR1 expression on Th17
cells in early CIA (Figure 7A–C). We speculate that theenhanced expression of S1PR1 on Th17 cells after E2
treatment could be a result of decreased levels of S1P
within the LNs of these mice, because high levels of S1P
lead to internalization of S1PR1 [32]. However, according
to the literature, levels of S1P within LNs are extremely
low compared with lymph and blood, and therefore only
S1P levels in serum were assessed [33]. Nonetheless, E2
did not influence serum levels of S1P (Figure 7D). Further-
more, the migratory function of S1PR1 could be modu-
lated by other receptors, such as S1PR4 and CD69.
Increased expression of S1PR4 and CD69 can, via different
mechanisms, attenuate S1PR1-mediated chemotaxis of T























































Figure 7 Th17 S1PR1 expression in lymph nodes in early collagen-induced arthritis. DBA/1 mice were ovariectomized, subjected to
collagen-induced arthritis (CIA) and treated with 17β-estradiol (E2; 0.83 μg/day) or placebo. (A–C) Frequency of sphingosine-1-phosphate receptor
1-positive (S1PR1+) cells of T helper 17 (Th17) (A) and median fluorescence intensity (MFI) of S1PR1 on Th17 cells (B,C) in lymph nodes (LNs) from
CIA mice (day 14, single experiment with n = 10 mice/group). (B) Representative fluorescence-activated cell sorting analysis plot where fluorescence
minus one is used as a control. (D) S1P levels in serum of mice with CIA at day 14 were determined by enzyme-linked immunosorbent assay (single
experiment, n = 9 or 10 mice/group). To improve normal distribution of data, some data were log-transformed prior to statistical analysis (A,C). Bars or
lines show arithmetic mean ± SEM. Student’s t-test (**P <0.01).
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analysis of CD69 and other S1PRs, are therefore indis-
pensable to fully understand the effects of estrogen on the
S1P-S1PR system. Another possible explanation for the
E2-mediated retention of Th17 cells, despite enhanced ex-
pression of S1PR1, could be that CCR6-CCL20 simply
overrides the S1PR1-S1P-mediated migration of cells.
We cannot exclude that E2 might actually exert a
stimulatory effect on the Th17 population in the induc-
tion phase of CIA. However, estrogen has been shown to
regulate Th17 cells in various disease models [21,43].
Furthermore, our results demonstrating a decreased
number of Th17 cells in the joints in the symptomatic
phase of CIA (Figure 3B) do not favor a general Th17-
inducing effect of E2. In addition, estrogen not only dir-
ectly inhibits CIA but also delays the onset of disease,
which is in accordance with our suggested model. The
E2-induced Th17 cell increase in LNs in early CIA dis-
appeared in the arthritic phase (Figure 4B, day 35). One
possible explanation might be that Th17 cells retained in
the LNs are undergoing apoptosis, possibly due to lack
of signals required for the maintenance and pathogen-
icity of the Th17 lineage, such as IL-23 and transforming
growth factor β3 [44].
All mice used in this study were OVX; hence, we can
only speculate on how endogenous estrogens affect
Th17 cells. However, the E2 dose used in the present
study is considered to be physiologically relevant [26].
We have previously shown that endogenous estrogens
are sufficient to reduce CIA, because OVX mice display
more severe arthritis compared with sham-operated
mice [45]. Moreover, it has been demonstrated that re-
moval of estrogen by OVX results in modulation ofTh17 cells in bone marrow and IL-17 levels in serum (in
otherwise healthy mice), indicating that endogenous es-
trogens indeed regulate Th17 cells [43].
RA and multiple sclerosis are two diseases with many
common features, such as a Th17-driven pathology,
where estrogen treatment has been shown to be benefi-
cial, both in experimental animal models and in humans
[4,6,46]. Studies of experimental multiple sclerosis, EAE,
have elucidated some mechanisms in the E2-mediated
inhibition of the disease. Lelu et al. showed that ERα ex-
pression specifically in CD4+ T cells is required for the
inhibiting effect of E2 in EAE and also that E2 reduces
the frequency of splenic Th17 cells in an ERα-dependent
manner [21]. In accordance, we have recently shown
that the inhibitory effects of E2 on arthritis in CIA and
AIA, and the associated bone loss in CIA, are clearly
mediated via ERα [5,22]. In line with this, we report that
the E2-induced Th17 cell increase in LNs is dependent
on ERα (Figure 4F). Moreover, IL-17 has been ascribed a
role as a mediator of bone loss induced by estrogen
deprivation, which highlights the necessity of further
studies in this field [43,47].
Conclusions
In this study, we comprehensively characterized effects
of estrogen on Th17 cells in experimental RA, demon-
strating that estrogen regulates localization of Th17 cells
during the development of arthritis, by increasing LN
Th17 in early arthritis in an ERα-dependent manner and
decreasing joint Th17 in established arthritis. We report
that E2 influences Th17 migratory pathways in arthritis,
suggesting that E2 treatment might result in Th17 cell
retention in LNs thus preventing migration of Th17 cells
Andersson et al. Arthritis Research & Therapy  (2015) 17:32 Page 11 of 12to joints. Our study increases the understanding of the
role of estrogen in autoimmune arthritis and opens up
new fields for research concerning the sex bias in auto-
immune disease.
Additional file
Additional file 1: Figure S1. CCR7 expression and corresponding
lymph node chemokine expression after estrogen treatment.
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